Relmada Therapeutics

RLMD

Biotechnology · Healthcare

Price

$5.24

-0.22 (-4.03%)

Market Cap

$549.6M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+124.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 17.6M (2021) → 39.5M (2025)

Relmada Therapeutics is a small biotech company focused on developing new drugs to treat brain and mental health disorders. Its main drug candidate is REL-1017, also called esmethadone, which is designed to work as an add-on treatment for adults with major depressive disorder (MDD) who have not responded well to existing antidepressants. The company does not yet sell any approved products and is still in the clinical development stage.

Relmada currently generates no product revenue, which explains its zero gross margin and negative returns. It funds operations through equity raises and relies entirely on the success of its drug pipeline. The company is based in the United States and operates at a small scale typical of pre-revenue biotechs. The central risk is that REL-1017 must still gain FDA approval, and any clinical trial failure or regulatory setback could severely impact the company's future, since it has no other approved product to fall back on.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+62.1% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$744,560/ year

↓ Declining (-98% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

17.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~2 months

$10M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Relmada Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-8.9%

Weak — -8.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial